VYNE - Microcap Vyne Therapeutics surges 26% following H.C. Wainwright buy initiation

Shares in VYNE Therapeutics (VYNE +31.8%), a tiny biotech with a market cap of ~$62.6M, are surging today following a buy initiation from H.C. Wainwright. The firm has a $7 price target (669% return). Analyst Joseph Pantginis says that the company has a "reinvigorated" pipeline focused on skin disease treatments. VYNE's lead candidate is FCD105, a foam combination of minocycline and adapalene for acne vulgaris, in phase 2. The company expects to start a phase 2b trial of FMX114, a gel combination of Xeljanz (tofacitinib) and Gilenya (fingolimod) for atopic dermatitis in 1H 2022. Read more about a phase 1 trial of FMX114.

For further details see:

Microcap Vyne Therapeutics surges 26% following H.C. Wainwright buy initiation